临床与生化炎症在银屑病关节炎患者结构进展中的作用
该研究基于英夫利西单抗多国银屑病关节炎对照试验2中74例安慰剂治疗患者,分析临床炎症(肿胀关节计数)和生化炎症(C反应蛋白)对结构进展的影响。结果显示,时间平均肿胀关节计数(OR 1.24,95%CI 1.04-1.47,p=0.016)和时间平均C反应蛋白(OR 6.08,95%CI 1.12-33.03,p=0.036)均与影像学进展相关;无临床和生化炎症时进展最小,两者同时存在时进展最大(p=0.05)。
要点
- 时间平均肿胀关节计数每增加1个单位,结构进展OR为1.24(95%CI 1.04-1.47,p=0.016)。
- 时间平均C反应蛋白每增加1 mg/dL,结构进展OR为6.08(95%CI 1.12-33.03,p=0.036)。
- 无临床和生化炎症时进展最小,两者同时存在时进展最大(p=0.05)。
核心结论
- 在银屑病关节炎患者中,临床炎症和生化炎症均对结构进展有影响;无两者时进展最小,有其一者居中,两者兼有者进展最大。
研究设计与样本
- 分析英夫利西单抗多国银屑病关节炎对照试验2中74例安慰剂治疗患者,获取基线和第1年影像的改良Sharp/van-der-Heijde总评分,以及第1年后半段5次测量的肿胀关节计数和C反应蛋白水平,计算时间平均值并用逻辑回归评估对结构进展的影响。
主要发现
- 时间平均肿胀关节计数进展OR为1.24(95%CI 1.04-1.47;p=0.016),时间平均C反应蛋白进展OR为6.08(95%CI 1.12-33.03;p=0.036)。
- 二分类后,时间平均肿胀关节计数阳性组与阴性组影像学进展分别为1.05±3.21和0.56±2.30;时间平均C反应蛋白阳性组与阴性组分别为1.14±3.23和0.05±2.37。
- 仅一项炎症变量异常时进展居中,随炎症增加影像学进展增加(p=0.05)。
关键数值与推荐
- 时间平均肿胀关节计数截断值为2/66关节,时间平均C反应蛋白截断值为0.5 mg/dL,据此将患者分为活动性(+)或非活动性(-)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the contribution of clinical and biochemical inflammation to structural progression of patients with psoriatic arthritis (PsA). METHODS: We analysed patients from the Infliximab Multinational Psoriatic Arthritis Controlled Trial 2 trial (infliximab vs placebo). We obtained total modified Sharp/van-der-Heijde Scores from baseline and year one images, and swollen joint counts (SJC) and levels of C reactive protein (CRP) throughout the second half of year 1 (5 measurements) from 74 placebo-treated patients. We computed radiographic progression, time-averaged SJC (taSJC) and CRP (taCRP) values and assessed their impact on structural progression by logistic regression analysis. We further categorised patients as 'active' (+) or 'inactive' (-) based on their taSJC (cut-off point: 2/66 joints) and taCRP (cut-off point: 0.5 mg/dL) and compared radiographic progression across three groups (double inactive, single active, double active). RESULTS: ORs for progression were 1.24 (95 % CI 1.04 to 1.47; p=0.016) for taSJC and 6.08 (95 % CI 1.12 to 33.03; p=0.036) for taCRP. When predictors were dichotomised (+ vs -), differences were maintained between taSJC+ and taSJC- patients (1.05±3.21 and 0.56±2.30, respectively), as well as for taCRP+ vs taCRP- patients (1.14±3.23 and 0.05±2.37, respectively). Progression was intermediate in the presence of abnormalities of one but not the other inflammatory variable, indicating increasing radiographic progression with increasing inflammation (p=0.05). CONCLUSION: In patients with PsA, both clinical and biochemical inflammation have an impact on structural progression. Overall, progression is smallest in the absence of both clinical and biochemical inflammation, higher when either clinical or biochemical inflammation is present and highest with both clinical and biochemical inflammation.
引用
- Borst C, Alasti F, Smolen JS, et al. Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis. RMD Open. 2021. PMID: 34880129. doi:10.1136/rmdopen-2021-002038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。